Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients



Status:Recruiting
Conditions:Cardiology, Cardiology, Hospital
Therapuetic Areas:Cardiology / Vascular Diseases, Other
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:March 2016
End Date:February 2017
Contact:Tyler Lewis
Email:lewist07@nyumc.org

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The primary purpose of this study is to demonstrate that a continuous infusion of
intravenous (IV) heparin (UFH) for Venous thromboembolism (VTE) prophylaxis will restore
prophylactic levels of heparin in high-risk critically ill medical patients as compared with
guideline recommended subcutaneous heparin. Antifactor Xa assay, a laboratory test to
measure the anticoagulant activity of heparin, or the ability of heparin to thin the blood,
will be used to demonstrate that Intravenous administration is more effective.


Inclusion Criteria:

- Admission to the medical ICU (MICU)

- High-risk for Venous Thromboembolism (VTE) ≥ 1 of the following:

- Body Mass Index (BMI) ≥ 30 kg/m2

- Personal or family history of VTE

- Receiving vasopressors

Exclusion Criteria:

- Indication for therapeutic anticoagulation

- Evidence of deep vein thrombosis (DVT) on ultrasonography at admission

- Indwelling intrathecal, epidural, or other indwelling deep catheters

- Recent (< 3 months) International Society of Thrombosis and Haemostasis (ISTH) major
bleeding13

- Recent (< 3 months) major trauma

- Recent (< 3 months) neurosurgery or orthopedic surgery Pregnancy

- Contraindication to heparin or heparin products
We found this trial at
1
site
New York University School of Medicine
550 1st Ave
New York, New York 10016
(212) 263-7300
Principal Investigator: John Papadopoulos, MD
New York University School of Medicine NYU School of Medicine has a proud history that...
?
mi
from
New York, NY
Click here to add this to my saved trials